Rhinocerebral Mucormycosis as a Sequelae of COVID-19 Treatment: A Case Report & Literature Review

This article was originally published here

J Oral Maxillofac Surg. 2021 Sep 20:S0278-2391(21)01119-8. doi: 10.1016/j.joms.2021.09.009. Online ahead of print.


A large volume of reports detailing a marked increase in Mucormycosis infections in India has filtered its way into world news articles. These patients frequently have 2 risk factors: recent treatment of COVID-19 with high dose steroids, and uncontrolled diabetes. Recently, at the University of Tennessee Medical Center in Knoxville, we successfully treated an uncontrolled diabetic patient with rhinocerebral Mucormycosis as a sequela of his COVID-19 treatment.

PMID:34655530 | DOI:10.1016/j.joms.2021.09.009